LTZ Therapeutics has closed a USD 38 million financing round led by Hillhouse Investment Group's GL Ventures, with participation from an international sovereign wealth fund as well as existing investors Shunwei, Unicorn Capital Partners, 5Y Capital, Lanchi Ventures, and Boyu Capital. Since its founding in 2022, the company has raised approximately USD 130 million.

The funds will accelerate the development of its myeloid cell engager (MCE) platform, specifically supporting the ongoing Phase I trial in the US for its lead candidate, LTZ-301, in relapsed or refractory non-Hodgkin lymphoma (NHL), and preparing to file an investigational new drug application (NDA) for a second candidate, LTZ-232.

The company's proprietary U-MCE platform is designed to engage and activate macrophages and monocytes to target diseased cells. LTZ-301 is a bispecific antibody (BsAb) targeting CD79b on B-cells.

PharmCube's NextBiopharm® database shows that, over the past ten months, LTZ has entered strategic collaborations with Eli Lilly and GSK, reflecting industry validation of its technology. Click here to request a free trial for NextBiopharm®.